Newsletter Signup | Join Community
Avastin delays progression of advanced ovarian cancer but does not appear to prolong survival.
Lynparza is an effective treatment for women with newly diagnosed and recurrent BRCA + and other mutated ovarian cancers
Combination of novel precision cancer medicines represents future direction of ovarian cancer treatment.
According to Lancet publication: PI3K - PARP inhibitor combination promising in ovarian cancer - future study warranted
There is no longer a “one-size-fits-all” approach to ovarian cancer treatment update on precision cancer medicines.
Chemotherapy and maintenance therapy options for recurrent ovarian cancer.
Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Looking for Long Term Survivors: https://www.massgeneral…
Great NOCC overview on maintenance therapy for ovarian cancer. …
Speak up and share your story of hope!https://mavendoctors…